Skip to main content
Smart Investors Daily
Thermo Fisher Scientific Inc. logo

NYSE · TMO

Thermo Fisher Scientific Inc.

Healthcare · Medical - Diagnostics & Research

$669.54

Down-$19.21 (-2.79%)

Updated Nov 22, 2026, 1:07 PM

SID Score

6.9/10

Composite research score

Smart Money

38/100

Bearish

Market cap
219.39B
P/E ratio
33.3
Dividend yield
0.32%
52-week range
$435.27 – $727.56
Volume
2.36M
Avg. volume
2.05M

Price performance · TMO

TMO price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 20, 2026

TMO closed at $669.54 after 20 trading sessions, down 2.24% for the selected period.

Last close
$669.54
Period change
-2.24%
Period low
$669.54
Period high
$721.63
Daily close
View OHLC price history
TMO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 20, 2026$689.72$692.00$667.94$669.542.36M
Nov 19, 2026$698.23$703.99$686.23$688.751.98M
Nov 18, 2026$680.78$694.12$680.29$692.742.08M
Nov 17, 2026$690.01$695.03$683.62$686.791.58M
Nov 16, 2026$699.08$701.5075$687.92$691.331.61M
Nov 13, 2026$701.42$702.03$689.71$700.221.84M
Nov 12, 2026$709.32$711.86$696.005$699.441.69M
Nov 11, 2026$719.69$727.56$716.47$717.711.82M
Nov 10, 2026$721.47$721.47$710.74$718.201.79M
Nov 9, 2026$699.25$723.08$692.39$721.632.27M
Nov 6, 2026$669.20$697.7775$661.60$694.762.09M
Nov 5, 2026$706.92$708.93$676.13$676.942.84M
Nov 4, 2026$708.00$712.1723$691.96$706.162.46M
Nov 3, 2026$677.92$700.20$671.9946$698.341.65M
Nov 2, 2026$699.86$699.86$679.40$682.651.85M
Oct 30, 2026$710.69$711.79$691.74$697.002.09M
Oct 29, 2026$703.575$711.8545$699.90$709.181.47M
Oct 28, 2026$691.83$710.84$691.0302$704.151.65M
Oct 27, 2026$680.96$700.99$676.00$693.021.83M
Oct 26, 2026$675.855$685.48$674.37$684.891.95M

Latest TMO news

The latest Smart Investors Daily articles mentioning TMO.

TMO research

Overview

Company profile and research snapshot.

Company profile

Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$625.78
Implied upside
—
Analysts
16
TMO recent ratings
DateFirmRatingTarget
Oct 30, 2026Argus ResearchBuy—
Oct 23, 2026CitigroupBuy—
Oct 22, 2026TD CowenBuy—
Oct 22, 2026StifelBuy—
Oct 22, 2026BairdOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 20, 2026

Thermo Fisher Scientific (TMO): A Sharp Valuation Shift Prompted the Strategy to Exit the Position

Nuance Investments, an investment advisor, released its Q3 2026 investor letter for “Nuance Concentrated Value Strategy”. The letter can be downloaded here. The Nuance Concentrated Value Composite is a value investment product focusing on equity or equity-linked securities of U.S.-based companies. The composite returned 10.32% YTD, compared to 19.22% for the Russell 3000® Value Index […]

Yahoo · Nov 20, 2026

Refrigerated Incubators - Global Strategic Business Report 2026: Capitalize on $209.9M Market Expansion with Thermo Fisher, Eppendorf, Binder, Bio-Rad and Memmert

Dublin, Nov. 20, 2026 (GLOBE NEWSWIRE) -- "Refrigerated Incubators - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global refrigerated incubators market was valued at US$637.0 million in 2025 and is projected to reach US$846.9 million by 2032, expanding at a compound annual growth rate (CAGR) of 4.2% during the forecast period. Market growth is supported by rising pharmaceutical and biotechnology research and development, expanding clinical trial acti

AI research layers

Interpretive context generated from the platform’s current data sources.

Thermo Fisher Scientific Inc. Stock Performance

Thermo Fisher Scientific Inc. shares closed at $692.74, reflecting a daily decline of approximately 1.05%, per SID market data. Despite this short-term pullback, the stock has demonstrated meaningful momentum over broader timeframes, gaining 1.09% over the past month, 11.94% over three months, and 10.45% over the trailing twelve months. The stock currently trades well above its 200-day moving average of $554.76, representing a premium of approximately 24.9%, while also sitting above its 50-day moving average of $673.85. The 14-day relative strength index stands at 44.8, indicating the stock resides in neutral territory without overbought or oversold conditions, according to Massive/Polygon technical data. Average daily trading volume registers at approximately 2.05 million shares. The company's beta of 0.902 indicates slightly lower volatility relative to the broader market, consistent with Thermo Fisher's positioning as a large-cap Healthcare sector constituent with a market capitalization of approximately $219.4 billion.

Thermo Fisher Scientific Inc. Valuation Analysis

Thermo Fisher Scientific currently trades at a price-to-earnings ratio of 33.30, positioning the stock at a premium relative to the broader market, per SID market data. The company's price-to-book ratio stands at 4.29, reflecting the market's valuation of the firm's intangible assets, brand strength, and intellectual property portfolio within the life sciences and diagnostics space. The PEG ratio registers at an elevated 577.17, suggesting that earnings growth expectations remain modest relative to the current earnings multiple, according to SEC filings. The company maintains a dividend yield of approximately 0.29%, indicating that Thermo Fisher prioritizes capital reinvestment and strategic acquisitions over shareholder cash distributions. Within the Healthcare sector, these valuation metrics reflect the company's classification as a premium-priced, quality compounder. The $219.4 billion market capitalization underscores Thermo Fisher's status as one of the largest companies in the scientific instruments and laboratory equipment industry globally.

Smart Money Activity for TMO

Thermo Fisher Scientific registers a composite smart money score of 44, corresponding to a neutral signal, per SID market data. The institutional component stands at a perfect 25 out of 25, reflecting robust conviction from large asset managers and institutional holders. However, other smart money categories present a more cautious picture. The insider score sits at 8.9 out of 25, with SEC Form 4 filings revealing 20 insider transactions over the past 90 days, comprising 6 purchases and 14 sales. This sell-to-buy ratio of approximately 2.3-to-1 indicates a net disposition trend among corporate insiders. The dark pool activity score registers at 8.5 out of 25, suggesting limited notable accumulation through off-exchange channels. Congressional trading activity scores just 1.6 out of 25, reflecting minimal reported positions among members of Congress, according to 13F institutional filings and congressional disclosure records. The divergence between strong institutional support and weaker insider sentiment creates a mixed smart money profile for the stock.

Thermo Fisher Scientific Inc. Earnings Outlook

Thermo Fisher Scientific has demonstrated a consistent pattern of exceeding analyst expectations across its three most recent reported quarters, according to company earnings reports. In the most recent quarter, the company posted earnings per share of $6.68 against a consensus estimate of $6.40, delivering a positive surprise of $0.28. The prior quarter produced EPS of $6.03 versus the $5.71 estimate, representing a beat of $0.32, the largest surprise in the current reporting cycle. The quarter before that showed EPS of $5.44 against a $5.23 estimate, a positive surprise of $0.21. This trajectory reveals sequential earnings growth from $5.44 to $6.03 to $6.68, reflecting quarter-over-quarter acceleration. The upcoming quarter carries an analyst consensus estimate of $5.71 per share, per analyst estimates. The consistent beat pattern across three consecutive quarters, with surprises ranging from $0.21 to $0.32, underscores management's ability to deliver results above market expectations.

Wall Street Analyst Ratings for TMO

Wall Street consensus on Thermo Fisher Scientific remains uniformly bullish, with all five most recent analyst actions reaffirming positive ratings, per Wall Street analyst reports. On October 30, 2026, Argus Research maintained its Buy rating on TMO. Following the company's earnings release, Citigroup reiterated a Buy rating on October 23, while both TD Cowen and Stifel maintained their Buy recommendations on October 22. Baird also reaffirmed its Outperform rating on October 22. Notably, none of these five analyst actions represented upgrades or downgrades; each maintained a prior bullish stance, indicating sustained conviction rather than a shift in sentiment. The clustering of four reaffirmations around October 22-23 aligns with the post-earnings review cycle, according to SID consensus data. The absence of any Hold, Underperform, or Sell ratings among recent coverage updates reflects broad agreement among major sell-side institutions regarding Thermo Fisher's fundamental positioning within the life sciences tools market.